

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



信銘生命科技集團有限公司
Aceso Life Science Group Limited
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 00474)

DISCLOSABLE TRANSACTION
COMPLETION OF SUBSCRIPTION OF SHARES INVOLVING ISSUE OF
CONSIDERATION SHARES UNDER GENERAL MANDATE

Reference is made to the announcements of the Company dated 30 January 2026 and 27 February 2026 (the “**Announcements**”). Unless otherwise defined, capitalized terms used in this completion announcement shall have the same meanings as those defined in the Announcements.

COMPLETION OF SUBSCRIPTION

The Board is pleased to announce that all the conditions as set out in the Subscription Agreement have been fulfilled on 3 March 2026 and the Completion has taken place on 3 March 2026 in accordance with the terms and conditions of the Subscription Agreement.

Upon Completion, IFGL will not become a subsidiary of the Company, but will be accounted for as financial assets at fair value through other comprehensive income of the Company.

1,476,350,000 Consideration Shares have been allotted and issued to the nominee of IFGL upon Completion.

EFFECTS ON THE ISSUE OF THE CONSIDERATION SHARES ON THE SHAREHOLDING STRUCTURE OF THE COMPANY

The shareholding structure of the Company before and after the Completion will be as follows:

Name of shareholders	Immediately before the Completion		Immediately after the Completion	
	Number of Shares	Approximate %	Number of Shares	Approximate %
Zhiliang Ou (<i>Note 1</i>)	733,752	0.01%	733,752	0.01%
Fok Chi Tak (<i>Note 1</i>)	60,871,152	0.82%	60,871,152	0.69%
Chan Ming Sun Johnathan (<i>Note 2</i>)	733,752	0.01%	733,752	0.01%
Lam Kwan Sing (<i>Note 2</i>)	733,752	0.01%	733,752	0.01%
Glory Century Limited (<i>Note 3</i>)	386,802,000	5.24%	386,802,000	4.37%
Century Golden Resources Investment Co., Ltd. (<i>Note 4</i>)	800,000,000	10.84%	800,000,000	9.03%
Li Shao Yu (<i>Note 5</i>)	4,120,683,115	55.82%	4,120,683,115	46.51%
IFGL (or its nominee(s))	–	–	1,476,350,000	16.67%
Other public shareholders	2,011,219,282	27.25%	2,011,219,282	22.70%
	<u>7,381,776,805</u>	<u>100.00%</u>	<u>8,858,126,805</u>	<u>100.00%</u>

Notes:

1. Dr. Zhiliang Ou and Mr. Fok Chi Tak, being the executive directors of the Company, are interested in 733,752 Shares and 60,871,152 Shares respectively as at the date of this announcement.
2. Mr. Chan Ming Sun Johnathan and Mr. Lam Kwan Sing, being the independent non-executive directors of the Company, each of them is interested in 733,752 Shares as at the date of this announcement.
3. Glory Century Limited is indirectly wholly owned by HTICI whose shares are listed on the Main Board of the Stock Exchange (Stock Code: 1341).
4. Based on the best information of the Company, each of Mr. Huang Shiyong and Mr. Huang Tao was deemed to be interested in 800,000,000 Shares held by Century Golden pursuant to the SFO by virtue of their controlling interest in Century Golden.
5. Those Shares were held directly by (i) Team Success Venture Holdings Limited as to 230,900,000 Shares and TRXY Development (HK) Limited as to 46,332,000 Shares, both are beneficially and wholly-owned by Ms. Li Shao Yu; and (ii) Ms. Li Shao Yu as to 3,843,451,115 Shares.

By Order of the Board
Aceso Life Science Group Limited
Zhiliang Ou
Executive Director

Hong Kong, 3 March 2026

As at the date of this announcement, the board of directors of the Company comprises two executive directors, namely Dr. Zhiliang Ou (J.P. (Australia)) and Mr. Fok Chi Tak; one non-executive director, namely Ms. Jiang Yang; and three independent non-executive directors, namely Mr. Chan Ming Sun Jonathan, Mr. Lam Kwan Sing and Mr. Mak Yiu Tong.